Intensity Therapeutics Faces Nasdaq Non-Compliance Notice

Intensity Therapeutics, Inc. ( (INTS) ) just unveiled an announcement.

On May 19, 2025, Intensity Therapeutics, Inc. received a notification from Nasdaq indicating non-compliance with the minimum stockholders’ equity requirement for continued listing on The Nasdaq Capital Market. The company has until July 3, 2025, to submit a plan to regain compliance. If the plan is accepted, an extension may be granted, but there is no assurance of acceptance or compliance. The notice does not immediately affect the company’s listing, but failure to comply could lead to delisting.

The most recent analyst rating on (INTS) stock is a Buy with a $8.50 price target. To see the full list of analyst forecasts on Intensity Therapeutics, Inc. stock, see the INTS Stock Forecast page.

Spark’s Take on INTS Stock

According to Spark, TipRanks’ AI Analyst, INTS is a Underperform.

Intensity Therapeutics faces significant challenges typical of a pre-revenue biotech firm, including negative financial metrics and bearish technical indicators. While recent corporate announcements about cancer treatment progress are promising, they do not outweigh the financial and technical difficulties. The overall score reflects these challenges, positioning the stock at the lower end of the scoring range.

To see Spark’s full report on INTS stock, click here.

More about Intensity Therapeutics, Inc.

Average Trading Volume: 169,075

Technical Sentiment Signal: Sell

For an in-depth examination of INTS stock, go to TipRanks’ Stock Analysis page.